The availability of a number of ALK inhibitors has complicated management of ALK patients, but in a long-term assessment of 110 patients with an ALK inhibitor, a remarkable OS for advanced ALK NSCLC patients of 6.8 years was reported with 78.4% of patients receiving another ALK inhibitor after first-line progression [44]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.